# PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

> **NCT04165174** · PHASE2 · UNKNOWN · sponsor: **Huazhong University of Science and Technology** · enrollment: 20 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** Terepril monoclonal antibody; Apatinib
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT04165174
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12
- **Primary completion:** 2020-11
- **Final completion:** 2020-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165174, "PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04165174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*